MedPath
EMA Product

Trimbow

Product approved by European Medicines Agency (EU)

Basic Information

Trimbow

Regulatory Information

EMEA/H/C/004257

Authorised

July 17, 2017

May 18, 2017

9

February 17, 2025

Company Information

Italy

Via Palermo 26/A 43122 Parma

CHIESI FARMACEUTICI S.P.A.

Active Substances Detail

Beclometasone dipropionateformoterol fumarate dihydrateGlycopyrronium bromide

Detailed Information

Therapeutic Indication

### Therapeutic indication Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. **COPD** Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1). **Asthma** Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Overview Summary

Trimbow is a medicine used in adults for treating moderate to severe chronic obstructive pulmonary disease (COPD) and asthma. In COPD, Trimbow is used for maintenance (continuing) treatment in patients whose disease is not adequately controlled despite treatment with a combination of two medicines consisting of a long-acting beta-2 agonist plus either an inhaled corticosteroid or a long-acting muscarinic receptor antagonist. Beta-2 agonists and muscarinic receptor antagonists help to widen the airways; corticosteroids reduce inflammation in the airways and lungs. In asthma, Trimbow is used for maintenance treatment in adults whose disease is not adequately controlled despite treatment with a long-acting beta-2 agonist plus a medium or high dose of inhaled corticosteroid, and who had one or more exacerbations (flare-ups) in the past year. Trimbow contains the active substances beclometasone, formoterol and glycopyrronium bromide.

© Copyright 2025. All Rights Reserved by MedPath